Researchers at the Icahn School of Medicine at Mount Sinai have developed a first-of-its-kind mRNA system that switches on therapeutic genes preferentially inside targeted cells-an advance demonstrated in studies in mice that could lay the groundwork for safer, more precise treatments for cancer and other diseases.